title: Enhancement of leukemia rejection by mice successfully treated for L1210 leukemia due to low dose compared to high dose VP-16.
abstract: We have earlier shown that VP-16 combined with Cyclosporin A (CsA) produces tumor specific immunity to L1210 leukemia in BDF/1 mice [Slater LM, Sweet P, Stupecky M, Reynolds JT. Cyclosporin A/VP-16 produced immunity to L1210 leukemia: the participation of cytotoxic CD(8) T-lymphocytes, Clin Immunol Immunopathol 1995;75:239-45]. Our current studies, designed to determine the role of VP-16 independently of CsA in this effect show that increased dose intensity of VP-16, in the absence of CsA, improves the frequency of 60 day survival of treated mice but impairs the ability of 60 day surviving mice to reject L1210 leukemia challenge. This impairment is associated with progressive diminution of mitogen responses by spleen cells harvested from tumor free VP-16 treated mice.
authors.affiliation: Division of Hematology/Oncology, Department of Medicine, University of California Irvine, Med Surge II Room 375B, Irvine, CA 92697-1875, USA. lmslater@uci.edu
authors.forename: Lewis M
authors.initials: LM
authors.lastname: Slater
authors.forename: Marie
authors.initials: M
authors.lastname: Stupecky
authors.forename: Paula
authors.initials: P
authors.lastname: Sweet
authors.forename: Kathryn E
authors.initials: KE
authors.lastname: Osann
mesh_terms: D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000627:therapeutic use*; D003208:Concanavalin A / Q000494:pharmacology; D016572:Cyclosporine / Q000627:therapeutic use; D003524:Cyclosporins / Q000627:therapeutic use; D004354:Drug Screening Assays, Antitumor; D005047:Etoposide / Q000008:administration & dosage / Q000627:therapeutic use*; D006084:Graft Rejection / Q000139:chemically induced; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007939:Leukemia L1210 / Q000188:drug therapy*; D008213:Lymphocyte Activation / Q000187:drug effects; D051379:Mice; D008811:Mice, Inbred DBA; D009368:Neoplasm Transplantation; D010835:Phytohemagglutinins / Q000494:pharmacology
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D003524:Cyclosporins; D007166:Immunosuppressive Agents; D010835:Phytohemagglutinins; D003208:Concanavalin A; D005047:Etoposide; D016572:Cyclosporine; C070272:valspodar